Double Manufacturing Deals for Sanofi


Aug 02, 2013

Two Sanofi companies have entered biomanufacturing deals with Vivus and Gallus Biopharmaceuticals. Sanofi subsidiary Sanofi Chimie has made an agreement with Vivus to manufacture and supply the active pharmaceutical ingredient (API) for erectile dysfunction drug avanafil (known as Stendra™ in the U.S. and Spedra™ in the EU) on an exclusive basis in the U.S. and other territories and on a semi-exclusive basis in the EU and Latin America.

Meanwhile, Genzyme, another Sanofi company, entered a multi-year development and manufacturing supply agreement with St. Louis-based CMO Gallus Biopharmaceuticals in which Gallus will provide process and method development, scale-up, clinical supply, and preparation for commercial manufacturing for an infused protein-based therapy targeting the rare disease Niemann-Pick type B. Read more